Cepheid Vice President Dr. Emily Winn-Deen Receives 2006 AACC Award For Outstanding Contributions To Clinical Chemistry Through Science And Technology

SUNNYVALE, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Cepheid today announced that Vice President for Strategic Planning and Business Development, Dr. Emily Winn-Deen, has received the 2006 award for Outstanding Contributions to Clinical Chemistry through Science and Technology by The Northern California section of the American Association for Clinical Chemistry (AACC).

“Dr. Winn-Deen is recognized as an outstanding Bay area scientist,” said Award committee chairman Jim Faix. “Dr. Winn-Deen was chosen to receive this award for her many contributions to advancing the field of molecular diagnostics.”

“In addition to her many business development activities, Dr. Winn-Deen is currently involved in leading the Company’s introduction of its first CE marked product for BCR/ABL in Europe. We congratulate Emily for this well deserved recognition in advancing the field of molecular diagnostics and are proud to have her as a part of the Cepheid management team,” said John Bishop, Cepheid’s Chief Executive Officer.

About Cepheid

Cepheid , based in Sunnyvale, Calif., is a leading developer, manufacturer and marketer of fully integrated systems that enable genetic assessment when and where it is needed. Founded in 1996, the company is commercializing its technology and products worldwide for research, medical, and industrial applications requiring assessment of the human genome, infectious disease and biothreat agents. See www.cepheid.com for more information.

About AACC

AACC is a society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry. The association was founded in 1948 and has 22 local sections throughout the U.S. The Northern California section represents members in Northern California, Nevada and Hawaii and is one of the AACC’s largest. Members nominate other members for one of three annual awards: Outstanding Contributions to Clinical Chemistry through Education, Outstanding Contributions to Clinical Chemistry through Science & Technology and the Harold Van Remortel Service Award. These awards, which are part of the Northern California section’s annual banquet, have been given since 1991. You can find more information about AACC by visiting www.aacc.org.

This press release contains forward-looking statements that are not purely historical regarding Cepheid’s or its management’s intentions, beliefs, expectations and strategies for the future, including those relating to growth opportunities in specified markets. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company’s current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: development and manufacturing problems; our ability to successfully obtain regulatory approvals and introduce new products in the clinical market; the performance and market acceptance of new products; the impact of competitive products and pricing; and underlying market conditions worldwide. Readers should also refer to the section entitled “Risk Factors” in Cepheid’s Annual Report on Form 10-K for 2004 and “Factors that Might Affect Future Results” in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

CONTACTS: At the Company: John L. Bishop John R. Sluis CEO, Cepheid CFO, Cepheid 408-541-4191 408-541-4191 john.bishop@cepheid.comjohn.sluis@cepheid.com At Financial Relations Board: Tricia Ross Investor/Analyst Information 617-520-7064 tross@financialrelationsboard.com

Cepheid

CONTACT: John L. Bishop, CEO, john.bishop@cepheid.com, or John R. Sluis,CFO, john.sluis@cepheid.com, both of Cepheid, +1-408-541-4191; orInvestor/Analyst Information, Tricia Ross of Financial Relations Board,+1-617-520-7064, tross@financialrelationsboard.com, for Cepheid

MORE ON THIS TOPIC